Acetylsalicylic acid resistance after renal transplantation

In Vivo. 2015 Jan-Feb;29(1):141-4.

Abstract

Background: Cardiovascular diseases are a leading cause of mortality after kidney transplantation. According to guidelines, acetylsalicylic acid (ASA) must be given as preventive antiplatelet therapy, but resistance to this drug is also well-known.

Patients and methods: A total of 214 renal transplant patients were included in our study and took 100 mg of ASA q.d. Aggregometry was performed to determine resistance. Twenty-four variables were examined using logistic regression analysis as possible causes of resistance.

Results: ASA resistance was observed in 40.18% of the patients. Resistance reduced concomitant statin therapy and significantly increased simultaneous cyclosporine therapy.

Conclusion: Our study assessed the post-transplant ASA resistance in a large population. Clarification of this matter is crutial, since one of the major preventive pharmacological therapies of cardiovascular mortality is not effective in a significant number of patients.

Keywords: Aggregometry; acetylsalicylic acid resistance; cardiovascular complication; platelet aggregation; transplantation.

MeSH terms

  • Adult
  • Aged
  • Aspirin / pharmacology
  • Aspirin / therapeutic use*
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Cyclosporine / adverse effects
  • Cyclosporine / therapeutic use
  • Drug Resistance*
  • Female
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Kidney Transplantation / adverse effects*
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / pharmacology
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Risk Factors

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Platelet Aggregation Inhibitors
  • Cyclosporine
  • Aspirin